Scientific Integrity Policy Updates At FDA, CDC Due For Completion In July
HHS-wide update will address agency integrity improvements in the wake of concerns that political considerations inappropriately influenced regulatory decisions related to COVID-19 during the Trump Administration, the General Accountability Office notes in a new report.
You may also be interested in...
The US watchdog agency accedes to three senators’ request to look into political pressures placed on the FDA and the CDC to alter the science behind their COVID-19 responses.
The US department that oversees the FDA says the agency acted beyond its authority in asking labs to file emergency use authorizations, asserting that only CLIA rules should apply.
Third Circuit is first of three federal appeals courts to issue a decision in multiple lawsuits over drug companies’ 340B contract pharmacy restrictions, which have led to conflicting lower court rulings on whether such restrictions are unlawful.